Literature DB >> 3233590

Piracetam in the treatment of different types of myoclonus.

J A Obeso1, J Artieda, N Quinn, J C Rothwell, M R Luquin, J Vaamonde, C D Marsden.   

Abstract

Forty patients with different clinical and electrophysiological types of myoclonus were treated with piracetam (18-24 g per day, p.o.) alone, or with other drugs (clonazepam, sodium valproate, and primidone) in different combinations. Piracetam in monotherapy improved the electrophysiological abnormalities in patients with cortical reflex myoclonus, but had no useful clinical effect. Sixteen patients obtained benefit from piracetam when given in combination with other antimyoclonic drugs; improvement was dramatic in two patients, moderate in seven and mild in seven. All patients showing some response to piracetam had myoclonus of cortical origin; however, five other patients with similar cortical myoclonus failed to improve when piracetam was added. Tolerance was excellent and side effects were minimal and transient. It is concluded that piracetam probably has an antimyoclonic action, but its potential value as a therapeutic tool for disabling myoclonus requires further study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3233590     DOI: 10.1097/00002826-198812000-00006

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  5 in total

Review 1.  An update and review of the treatment of myoclonus.

Authors:  Kelly Mills; Zoltan Mari
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

2.  Myoclonus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

3.  Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo.

Authors:  M Koskiniemi; B Van Vleymen; L Hakamies; S Lamusuo; J Taalas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-03       Impact factor: 10.154

4.  Effects of alcohol on myoclonus and somatosensory evoked potentials in dyssynergia cerebellaris myoclonica.

Authors:  C S Lu; N S Chu
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-10       Impact factor: 10.154

Review 5.  Myoclonus: Pathophysiology and Treatment Options.

Authors:  Ariel Levy; Robert Chen
Journal:  Curr Treat Options Neurol       Date:  2016-05       Impact factor: 3.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.